Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor

Fig. 4

Subgroup analysis of the hazard ratios for the risks of ischemic stroke (IS) (a) acute myocardial infarction (AMI) (b), and congestive heart failure (CHF) (c) for SGLT2i versus DPP4i among T2DM patients with concomitant peripheral artery disease after propensity score matching. In general, the subgroup analysis revealed consistent results for the risks of IS (a) AMI (b), and CHF (c) for SGLT2i versus DPP4i among patients aged \(\ge \) 75 years, the presence of chronic kidney disease (CKD) and established CV disease, consistent with the main analysis. The subgroup analysis indicated that SGLT2i reduced the risk of IS and AMI in patients with concomitant CKD but not in patients without CKD (p interactions = 0.02). Abbreviations: CKD chronic kidney disease, CV cardiovascular disease. Other abbreviations as in Figs. 1, 2, 3.

Back to article page